April 03, 2025

Pulmonary Embolism in ESKD: New Data on Risk, Outcomes

Fewer than half of patients with end-stage kidney disease who survived pulmonary embolism filled an anticoagulation prescription, yet PE recurrence rates were similar between those who did and did not receive anticoagulation (4.2% vs. 2.8%; P = .11), according to a new study.

Conexiant

April 02, 2025

Sleep Apnea Associated with Lung Cancer Risk

The impact of sleep apnea on lung cancer risk appears to be strongly influenced by biological sex, researchers find in a nationwide study of COPD patients.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 24, 2025

Sex Differences in Asthma and COPD Hospital Admission Outcomes: Study

Females with asthma had 'higher odds of readmission within 30 and 90 days' compared with males, according to a new study on sex differences in asthma and COPD outcomes.

Conexiant

March 20, 2025

Study Links Time to Lung Test Results

The odds of a positive bronchodilator response decrease by 8% per hour during the workday, researchers report in the SPIROTIMETRY study.

Conexiant

March 18, 2025

30-Month Study Tracks Post-COVID Health Risks

In a new study on the long-term health risks post–COVID-19 hospitalization, researchers reported an "increased risk of death or hospitalization for various organ disorders up to 30 months after discharge."

Conexiant

March 14, 2025

Fungal Biomarkers Identified in Pulmonary Hypertension

A study in BMC Medicine identifies airway fungal shifts in pulmonary hypertension, highlighting potential diagnostic biomarkers.

Conexiant

March 14, 2025

Standard Care Matches Lung Expansion Plan

The intervention did not lead to a significant reduction in the severity of PPCs compared with usual care, researchers reported in the PRIME-AIR trial.

Conexiant

March 13, 2025

FDA Chief Counsel Resigns Two Days In

U.S. FDA's chief counsel resigns amidst controversy surrounding her appointment and connections to mifepristone during the Biden administration.

Reuters